Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab to sorafenib as first-line treatment in advanced hepatocellular carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-06-26